<DOC>
	<DOC>NCT01719263</DOC>
	<brief_summary>This study is designed to demonstrate safety and efficacy in patients with severe upper lobe predominant emphysema. For validity of the study, the results will be compared to patients that receive optimal medical therapy.</brief_summary>
	<brief_title>Sequential Segmental Treatment of Emphysema With Upper Lobe Predominance (STEP-UP) Study</brief_title>
	<detailed_description />
	<mesh_term>Emphysema</mesh_term>
	<mesh_term>Pulmonary Emphysema</mesh_term>
	<criteria>Heterogeneous emphysema with upper lobe predominance in both lungs FEV1 between 20% and 45% predicted Residual volume (RV) &gt; 150% predicted Postrehabilitation 6minute walk test &gt; 140 meters More than 3 COPD related hospitalizations requiring antibiotics in past 12 months FEV1 &lt; 20% predicted DLCO &lt; 20% predicted or immeasurable DLCO Body mass index (BMI) &lt; 18kg/m2 or &gt; 32 kg/m2 History of any of the following: Left ventricular ejection fraction (EF) â‰¤ 40% Stroke Myocardial infarction or acute coronary syndrome in previous year Hospitalization due to left ventricular failure in previous 3 years</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>emphysema</keyword>
	<keyword>InterVapor</keyword>
	<keyword>treatments</keyword>
	<keyword>pulmonary rehabilitation</keyword>
	<keyword>lung volume reduction</keyword>
	<keyword>endoscopic lung volume reduction</keyword>
</DOC>